Cabozantinib Boosts Dual Immunotherapy in Advanced RCC Cabozantinib Boosts Dual Immunotherapy in Advanced RCC
Triplet therapy for advanced renal cell carcinoma may soon be an option, after results show that adding cabozantinib to dual immune checkpoint inhibition improved progression-free survival.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Carcinoma | Hematology | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma